Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have locally advanced or metastatic pancreatic cancer that has not responded to gemcitabine.

Key facts

Study ID

NCT00053222

Run by

University of Chicago

People needed

13

Starts

2003-02-01

Expected to finish

2007-07-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
• Evanston Northwestern Health Care - Evanston Hospital — Evanston, Illinois, United States
• Ingalls Memorial Hospital — Harvey, Illinois, United States
• LaGrange Memorial Hospital — LaGrange, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
• Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
• Fort Wayne Medical Oncology and Hematology, Incorporated — Fort Wayne, Indiana, United States
• CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
• Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph — Saint Joseph, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.